609 related articles for article (PubMed ID: 25677117)
1. The determination of crystal structures of active pharmaceutical ingredients from X-ray powder diffraction data: a brief, practical introduction, with fexofenadine hydrochloride as example.
Brüning J; Schmidt MU
J Pharm Pharmacol; 2015 Jun; 67(6):773-81. PubMed ID: 25677117
[TBL] [Abstract][Full Text] [Related]
2. Solving molecular crystal structures from X-ray powder diffraction data: the challenges posed by gamma-carbamazepine and chlorothiazide N,N,-dimethylformamide (1/2) solvate.
Fernandes P; Shankland K; Florence AJ; Shankland N; Johnston A
J Pharm Sci; 2007 May; 96(5):1192-202. PubMed ID: 17455337
[TBL] [Abstract][Full Text] [Related]
3. Absolute Configuration of Pharmaceutical Research Compounds Determined by X-ray Powder Diffraction.
Schlesinger C; Tapmeyer L; Gumbert SD; Prill D; Bolte M; Schmidt MU; Saal C
Angew Chem Int Ed Engl; 2018 Jul; 57(29):9150-9153. PubMed ID: 29409149
[TBL] [Abstract][Full Text] [Related]
4. Powder diffraction crystallography of molecular solids.
Harris KD
Top Curr Chem; 2012; 315():133-77. PubMed ID: 21952843
[TBL] [Abstract][Full Text] [Related]
5. Structural characterization of anhydrous naloxone- and naltrexone hydrochloride by high resolution laboratory X-ray powder diffraction and thermal analysis.
Sugimoto K; Dinnebier RE; Zakrzewski M
J Pharm Sci; 2007 Dec; 96(12):3316-23. PubMed ID: 17582810
[TBL] [Abstract][Full Text] [Related]
6. Tris(hydroxymethyl) aminomethane salt of ramipril: synthesis, structural characterization from X-ray powder diffraction and stability studies.
Bhattacharya A; Chattopadhyay B; Chakraborty S; Roy BN; Singh GP; Godbole HM; Rananaware UB; Mukherjee AK
J Pharm Biomed Anal; 2012 Nov; 70():280-7. PubMed ID: 22877875
[TBL] [Abstract][Full Text] [Related]
7. Conformational analysis of an acyclic tetrapeptide: ab-initio structure determination from X-ray powder diffraction, Hirshfeld surface analysis and electronic structure.
Das U; Naskar J; Mukherjee AK
J Pept Sci; 2015 Dec; 21(12):845-52. PubMed ID: 26434376
[TBL] [Abstract][Full Text] [Related]
8. Crystal morphologies and polymorphs in tolbutamide microcrystalline powder.
Li Destri G; Marrazzo A; Rescifina A; Punzo F
J Pharm Sci; 2013 Jan; 102(1):73-83. PubMed ID: 23042550
[TBL] [Abstract][Full Text] [Related]
9. Polymorphism of Alprazolam (Xanax): a review of its crystalline phases and identification, crystallographic characterization, and crystal structure of a new polymorph (form III).
de Armas HN; Peeters OM; Van den Mooter G; Blaton N
J Pharm Sci; 2007 May; 96(5):1114-30. PubMed ID: 17455340
[TBL] [Abstract][Full Text] [Related]
10. The principles underlying the use of powder diffraction data in solving pharmaceutical crystal structures.
Shankland K; Spillman MJ; Kabova EA; Edgeley DS; Shankland N
Acta Crystallogr C; 2013 Nov; 69(Pt 11):1251-9. PubMed ID: 24192168
[TBL] [Abstract][Full Text] [Related]
11. Nimustine hydrochloride: the first crystal structure determination of a 2-chloroethyl-N-nitrosourea hydrochloride derivative by X-ray powder diffraction and solid-state NMR.
Bekö SL; Urmann D; Lakatos A; Glaubitz C; Schmidt MU
Acta Crystallogr C; 2012 Mar; 68(Pt 3):o144-8. PubMed ID: 22382550
[TBL] [Abstract][Full Text] [Related]
12. Quantification of crystalline forms in active pharmaceutical ingredient and tablets by X-ray powder diffraction.
Cooper VB; Pearce GE; Petts CR
J Pharm Pharmacol; 2003 Sep; 55(9):1323-9. PubMed ID: 14604477
[TBL] [Abstract][Full Text] [Related]
13. Quantitative phase analyses through the Rietveld method with X-ray powder diffraction data of heat-treated carbamazepine form III.
Antonio SG; Benini FR; Ferreira FF; Rosa PC; Paiva-santos Cde O
J Pharm Sci; 2011 Jul; 100(7):2658-64. PubMed ID: 21259240
[TBL] [Abstract][Full Text] [Related]
14. Structure determination from conventional powder diffraction data: application to hydrates, hydrochloride salts, and metastable polymorphs.
Stephenson GA
J Pharm Sci; 2000 Jul; 89(7):958-66. PubMed ID: 10861598
[TBL] [Abstract][Full Text] [Related]
15. Clarithromycin form I determined by synchrotron X-ray powder diffraction.
Noguchi S; Miura K; Fujiki S; Iwao Y; Itai S
Acta Crystallogr C; 2012 Feb; 68(Pt 2):o41-4. PubMed ID: 22307251
[TBL] [Abstract][Full Text] [Related]
16. The methanol disolvate and the dihydrate of fexofenadine, an antihistamine drug.
Tessler L; Goldberg I
Acta Crystallogr C; 2005 Dec; 61(Pt 12):o707-10. PubMed ID: 16330854
[TBL] [Abstract][Full Text] [Related]
17. Structure determination of forms I and II of phenobarbital from X-ray powder diffraction.
Platteau C; Lefebvre J; Hemon S; Baehtz C; Danede F; Prevost D
Acta Crystallogr B; 2005 Feb; 61(Pt 1):80-8. PubMed ID: 15659860
[TBL] [Abstract][Full Text] [Related]
18. Isostructurality among solvates of cabazitaxel: X-ray structures and new solvates preparation.
Xu W; Gong N; Yang S; Zhang N; He L; Du G; Lu Y
J Pharm Sci; 2015 Apr; 104(4):1256-62. PubMed ID: 25675889
[TBL] [Abstract][Full Text] [Related]
19. Rietveld refinement of a wrong crystal structure.
Buchsbaum C; Schmidt MU
Acta Crystallogr B; 2007 Dec; 63(Pt 6):926-32. PubMed ID: 18004047
[TBL] [Abstract][Full Text] [Related]
20. A quick method for the quantitative analysis of mixtures. 1. Powder X-ray diffraction.
Dong W; Gilmore C; Barr G; Dallman C; Feeder N; Terry S
J Pharm Sci; 2008 Jun; 97(6):2260-76. PubMed ID: 17876772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
